Previous Close | 9.17 |
Open | 9.24 |
Bid | 8.28 x 1100 |
Ask | 8.63 x 800 |
Day's Range | 8.84 - 10.03 |
52 Week Range | 2.41 - 11.10 |
Volume | |
Avg. Volume | 1,685,060 |
Market Cap | 698.665M |
Beta (5Y Monthly) | 2.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.44 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32.67 |
Subscribe to Yahoo Finance Plus to view Fair Value for MNMD
NEW YORK, March 11, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in Miami, FL from March 11-13, 2024.
Key Takeaways; Cannabis Sector Key Takeaways; Psychedelic Sector In a rollercoaster week for MSOs, the cannabis industry faced both triumphs and challenges. Despite many positive Q4 reports in late February, this week witnessed an unusual trend as only a few large MSO reported their financials. Surprisingly, the market responded with increased selling even after companies […]
NEW YORK, March 07, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 per common share. In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,50